Physician profile
Denise E Herrera
NPI 1093276230
$1,485.03
in general payments reported to CMS, 2019-2025
14 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $23.30 · 2023: $465 · 2024: $393 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $375.62 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $137.86 | 2024 | Spravato |
| Sumitomo Pharma America, INC. | $124.99 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $124.36 | 2025 | Auvelity |
| Axonics, INC. | $116.84 | 2023 | Axonics |
| Abbvie INC. | $114.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $114.14 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $97.44 | 2024 | Daybue |
| Cvrx, INC. | $88.53 | 2025 | Barostim Neo System |
| Medicem INC. | $64.58 | 2023 | |
| Coloplast Corp | $40.35 | 2023 | Altis |
| Pfizer INC. | $39.36 | 2024-2025 | |
| Biogen, INC. | $23.30 | 2022 | |
| Abbott Laboratories | $22.67 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.